Compare · GILD vs TECX
GILD vs TECX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Tectonic Therapeutic Inc. (TECX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and TECX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $155.82B, about 289.1x TECX ($538.9M).
- Over the past year, GILD is up 14.0% and TECX is up 13.7% - GILD leads by 0.3 points.
- GILD has been more active in the news (20 items in the past 4 weeks vs 1 for TECX).
- GILD has more recent analyst coverage (25 ratings vs 11 for TECX).
- Company
- Gilead Sciences Inc.
- Tectonic Therapeutic Inc.
- Price
- $125.46-2.11%
- $28.64-1.85%
- Market cap
- $155.82B
- $538.9M
- 1M return
- -4.46%
- -0.52%
- 1Y return
- +13.97%
- +13.65%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2018
- News (4w)
- 20
- 1
- Recent ratings
- 25
- 11
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Latest TECX
- Tectonic Therapeutic upgraded by Raymond James with a new price target
- Tectonic Therapeutic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Tectonic Therapeutic Inc.
- Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
- Chief Medical Officer Ruddy Marcella K. sold $31,950 worth of shares (1,065 units at $30.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 67,682 units (SEC Form 4)
- SEC Form DEFA14A filed by Tectonic Therapeutic Inc.
- SEC Form DEF 14A filed by Tectonic Therapeutic Inc.
- Tectonic Therapeutic Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
- Stifel initiated coverage on Tectonic Therapeutic with a new price target